The dust has settled! The third batch of collection in Zhejiang Province does not involve growth hormone, and related concept stocks have risen slightly

【Pharmaceutical Network Pharmaceutical Stock Market】As of the close of trading on September 19, 2022, Changchun Gaoxin, the head enterprise of growth hormone, reported 161.
52 yuan, with a slight increase of 0.
93% in stock price, a turnover of 571 million yuan, and a turnover rate of 0.
93%.

In addition, Great Eastern rose slightly by 0.
42% and was quoted at 4.
76 yuan
.

On the news side, recently, Zhejiang Province issued the third batch of public medical institutions in the province of drugs centralized procurement announcement, procurement varieties catalog shows that this collection involves a total of 22 varieties, does not include growth hormone
.

For pharmaceutical companies, Jicai is like the sword
of Damocles.

Previously, the news about the collection of growth hormone was blown in many places such as Guangdong Province and Fujian Province, and the related concept stocks fell significantly
.

Among them, Changchun High-tech stock price from the beginning of 2022 to date, the stock price has fallen by nearly 40
%.

Guangdong Province in January this year clearly included recombinant human growth hormone into the Guangdong Alliance collection, this news triggered a big dive in Changchun high-tech stock price, 3 consecutive days of decline
.

In order to boost confidence in the market, Changchun Gaoxin stated in February that it abandoned the bidding of Guangdong Alliance water needle mining, and then Changchun Gaoxin's stock price improved
slightly.

On August 17, the news that "Zhejiang Province will carry out growth hormone collection" was reported on the Internet, although it was a false shot, but the Changchun high-tech stock price still fell to a halt on that day, closing at 202.
10 yuan / share, and the market value evaporated by nearly 10 billion
.

Nowadays, the third batch of documents in Zhejiang Province that do not contain growth hormone have been officially released, which can also be regarded as the dust landing
.

However, in early September, Fujian Province also issued a document to clarify that the collection of growth hormone will be carried out, and this collection involves two specifications
of recombinant human growth hormone with 4IU and 10IU.

For this collection, Changchun High-tech has recently responded that the above specifications and models correspond to the company's growth hormone powder needles, and the company, as an enterprise that won the bid in the previous year and the number of platform procurement, will actively track and pay attention to policy changes, actively participate in and fully and reasonably formulate response plans, actively and effectively carry out statements and reports to relevant departments and agencies, and take into account the interests of the company and shareholders in accordance with laws and regulations to ensure the
。
According to the 2022 semi-annual report, the company achieved revenue of 5.
831 billion yuan in the first half of the year, an increase of 17.
5% year-on-year; Net profit attributable to the mother was 2.
120 billion yuan, an increase of 10.
21%
year-on-year.

From the perspective of Changchun Gaoxin's growth hormone business, its core subsidiary Kinsey Pharmaceutical is mainly responsible for the production of recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection) and other growth hormone products
.

The income of Kinsey Pharmaceutical is also the main source of income for Changchun Gaoxin
.

According to the semi-annual report, in the first half of 2022, Kinsey Pharmaceutical achieved revenue of 4.
962 billion yuan and net profit attributable to the mother of 2.
191 billion yuan, up 17%
year-on-year.

According to this figure, Kinsey Pharmaceutical's revenue contribution to Changchun High-tech accounted for more than 85%, and its net profit attributable to the mother has been higher than the net profit of
the parent company Changchun Gaoxin.

In addition to the growth hormone business, Changchun High-tech also has a "troika" such as vaccine business and proprietary Chinese medicine, but the semi-annual report shows that in the first half of the year, its vaccine sector and proprietary Chinese medicine sector are not strong, of which vaccine subsidiary Baike Bio achieved operating income of 441 million yuan in the first half of the year, down 24.
28% year-on-year; Net profit attributable to the mother was 73.
5717 million yuan, down 46.
83%
year-on-year.

Huakang Pharmaceutical, a subsidiary of proprietary Chinese medicine, also contributed a negligible amount of revenue, achieving revenue of 305 million yuan and net profit attributable to the mother of only 16 million yuan
.

It can be seen from this that Changchun High-tech relies on the growth hormone business, and it is reasonable for investors to be sensitive to the news of
growth hormone collection.

It is worth mentioning that Changchun High-tech is also attaching importance to innovation and research and development
.

In the first half of the year, the company's R&D investment reached 682 million yuan, an increase of 52.
62% year-on-year, the company said, mainly due
to Kinsey Pharmaceutical's increased R&D investment.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.